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Highlights
 Total cross-sectional SPSS area (TSA) predicts survival in
support the clinical use of total cross-
sectional SPSS area for risk stratificationpatients with advanced chronic liver disease.
 The cut-off for TSA that is associated with worse survival
corresponds to a single shunt of >10 mm diameter.
 This study may impact on the clinical use of TSA/SPSS for risk
stratification and decision-making in the management of
patients with cirrhosis.https://doi.org/10.1016/j.jhep.2019.12.021
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Lay summary
The prevalence of spontaneous portosys-
temic shunts (SPSS) is higher in patients
with more advanced chronic liver disease.
The presence of more than 1 SPSS is
common in advanced chronic liver disease
and is associated with the development of
hepatic encephalopathy. This study shows
that total cross-sectional SPSS area (rather
than diameter of the single largest SPSS)
predicts survival in patients with
advanced chronic liver disease. Our results
and decision-making in the management
of SPSS.s is an open access article under the CC BY-NC-ND license
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Journal of Hepatology 20CT scans of 908 cirrhotic patients with SPSS were evaluated for
TSA. Clinical and laboratory data were recorded. Each detected
SPSS radius was measured and TSA calculated. One-year survival
was the primary endpoint and acute decompensation (oHE,
variceal bleeding, ascites) was the secondary endpoint.
Results: A total of 301 patients (169 male) were included in the
training cohort. Thirty percent of all patients presented with >1
SPSS. A TSA cut-off of 83 mm2 was used to classify patients with
small or large TSA (S-/L-TSA). Patients with L-TSA presented with
higher model for end-stage liver disease score (11 vs. 14) and
more commonly had a history of oHE (12% vs. 21%, p <0.05).
During follow-up, patients with L-TSA experienced more oHE
episodes (33% vs. 47%, p <0.05) and had lower 1-year survival
than those with S-TSA (84% vs. 69%, p <0.001). Multivariate
analysis identified L-TSA (hazard ratio 1.66; 95% CI 1.02–2.70,
p <0.05) as an independent predictor of mortality. An indepen-
dent multicentric validation cohort of 607 patients confirmed
that patients with L-TSA had lower 1-year survival (77% vs. 64%,20 vol. 72 j 1140–1150
p <0.001) and more oHE development (35% vs. 49%, p <0.001)
than those with S-TSA.
Conclusion: This study suggests that TSA >83 mm2 increases the
risk for oHE and mortality in patients with cirrhosis. Our results
support the clinical use of TSA/SPSS for risk stratification and
decision-making in the management of patients with cirrhosis.
Lay summary: The prevalence of spontaneous portosystemic
shunts (SPSS) is higher in patients with more advanced chronic
liver disease. The presence of more than 1 SPSS is common in
advanced chronic liver disease and is associated with the
development of hepatic encephalopathy. This study shows that
total cross-sectional SPSS area (rather than diameter of the single
largest SPSS) predicts survival in patients with advanced chronic
liver disease. Our results support the clinical use of total cross-
sectional SPSS area for risk stratification and decision-making
in the management of SPSS.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In the course of liver cirrhosis, the development of portal hyper-
tension is amajor driver of complications and therefore a frequent
cause of acute decompensation (AD).1,2 ADmay lead to a systemic
inflammatory response and progress to acute-on-chronic liver
failure (ACLF), a syndrome with high short-term mortality.3–6
Portal hypertension also drives the development of spontaneous
portosystemic shunts (SPSS) in patients with cirrhosis.
The association of SPSS or surgical/interventional shunting
with hepatic encephalopathy is well-known and the first em-
bolizations of SPSS, aimed at limiting the complications of portal
hypertension, were reported more than 30 years ago.7–9 How-
ever, since then, few reports on the role of SPSS in cirrhosis and
their possible treatment have been published.10–14 A large mul-
ticentric study confirmed the association of a single large
(diameter >8 mm) SPSS with the occurrence of hepatic en-
cephalopathy.15 Other reports have also demonstrated that
interventional embolization of SPSS can improve refractory he-
patic encephalopathy and liver failure in selected patients.16,17
Since the procedure of SPSS-embolization is invasive and in
many cases requires direct portal venous access, there is an open
discussion as to whether or when the procedure is indi-
cated.12,18–20 As a result, recommendations for the management
of SPSS are still missing from current guidelines.2,21–23
The presence of SPSS and especially their cumulative size has
not been associated with hard endpoints such as survival. From a
pathophysiological point of view the total cross-sectional shunt
area of an SPSS (or cumulative area of several SPSS) may reflect
the portosystemically shunted blood volume24 more accurately
than SPSS diameter. With the improved quality of imaging,
especially with CT, the detection of SPSS in clinical routine is
feasible and reliable. This present study aimed to evaluate the
role of the combined cross-sectional area of all SPSS, as a sur-
rogate marker of portosystemically shunted blood volume, in the
natural course of patients with liver cirrhosis.
Patients and methods
Study population
For this retrospective study, a total of 301 patients from the Uni-
versity Hospital of Bonnwere identified for inclusion as a training
cohort. Inclusion criteria were age 18 years or older, diagnosis ofJournal of Hepatology 20cirrhosis (clinical, radiologic or histologic) and SPSS of at least 5
mmof diameter in CTscans betweenOctober 2006 and April 2016.
Since precisionwas needed tomeasure SPSS diameter, aminimum
diameter of >5 mm was considered by our radiologist to provide
accurate SPSS size. The date of CT scan was defined as baseline.
Exclusion criteria were presence of hepatocellular carcinoma
beyond Milan criteria, previous transjugular intrahepatic porto-
systemic shunt (TIPS) or surgical shunt, anymedical conditionwith
expected survival of less than 6months, presence of neurologic, or
psychiatric disorder preventing a proper hepatic encephalopathy
evaluation and absence of critical information in the medical his-
tory.15 The validation cohort was formed of 607 consecutive pa-
tients, identified between 2010 and 2015, with the same selection
criteria as the training cohort from the rest of the participating
centers in the previously published multicenter study.15 Although
excluding small SPSSof less than5mmwasnot anoriginal criterion
in the prior multicenter study, it was applied to the validation
cohort for consistency. In all patients, cross-sectional area of all
detectable SPSS was assessed and calculated in CT scans. Clinical
and laboratory blood analysis data was followed up until end of
follow-up, death or liver transplantation (LT).
The primary endpoint was 1-year survival and secondary
endpoints were acute decompensations (hepatic encephalopa-
thy, variceal bleeding and ascites) during follow-up.
The local ethics committee of the participating centers
approved the study. The study was performed in accordance
with the Helsinki Declaration.
Assessment of SPSS parameters
All CT scans were reviewed by radiologists with expertise in liver
diseases. SPSS were defined as previously described.15 The
radiological study protocol is shown in the supplementary
materials and methods. All CT scans were screened for any
SPSS by scrolling through the abdominal CT scan in the axial
plane. If available, portal venous phase was preferred. The radi-
ologists looked for any additional veins leaving the inferior vena
cava, portal vein, splenic vein, right/left renal vein and superior/
inferior mesenteric vein. The presence of SPSS was verified in the
coronal and sagittal plane.
The position of the SPSS with the largest diameter was then
identified. At this position the short-axis diameter was recon-
structed and measured between both walls of the vessel.
The607CTscans fromthevalidation cohortwere reviewedagain
to measure the total cross-sectional SPSS area (TSA) for the present
study by the same radiologists who evaluated them in the prior
study.15 We have chosen to measure the cross-sectional area
instead of the diameter because more than 1 SPSS can occur in pa-
tientswith livercirrhosis andportalhypertension.15Though thesum
of diameters of all SPSS can be the same, the sum of cross-sectional
areas can be vastly different as shown in Fig. S1. We hypothesized
that TSA reflects the shunted blood volume better than diameters.
For each SPSS we calculated the area by the formula pr2. All SPSS
areas were then summed up to calculate the TSA for each patient.
The diameters of the SPSS were measured twice (initial data
were collected from the previous study by Simón-Talero et al.;15
for the current work, all the CTs were reviewed again by the
same expert radiologists). Therefore, the intra-rater variability of
the measurement has been calculated, with an intraclass corre-
lation coefficient of 0.95 (95% CI 0.94–0.96).
Esophageal and gastric varices were documented, but not
measured. Rectal varices were neither measured nor20 vol. 72 j 1140–1150 1141
Research Article Cirrhosis and Liver Failuredocumented. This is because, in both cases, the shunts are more
of a network than a single vessel that can be determined.
Statistical analysis
We performed descriptive statistics for all variables. Non-
parametric testing was used to compare different groups when
suitable. Paired non-parametric testing was used to compare
data of baseline and follow-up of the same patients. Correlation
of metric variables was performed using Spearman’s correlation.
For the selection of cut-off values of TSA, receiver-operating
characteristics analysis with 1-year survival as the endpoint
was calculated. To examine the impact of TSA on survival we
used a Kaplan-Meier curve with log-rank test. Univariate and
multivariate risk factor analyses were performed with Cox
regression for 1-year mortality and episodes of hepatic enceph-
alopathy as endpoints. Univariate analysis included general
characteristics (age, sex) and clinical conditions (hepatic
encephalopathy, hepatorenal syndrome, ascites, spontaneous
bacterial peritonitis) as well as prognostic score (model for end-
stage liver disease [MELD]) and laboratory parameters (Na,
creatinine, bilirubin, international normalized ratio [INR]) at
baseline. Multivariate analysis included all values with p <0.05
from univariate Cox regression. To avoid multicollinearity,
calculated scores such as MELD were not entered simultaneously
with their components, while scores with overlapping compo-
nents (Child-Pugh) were not entered simultaneously either.
Continuous variables are presented as median (range), unless
otherwise specified. Categorical variables are presented as ab-
solute cases and/or percentage. The intra-rater reliability was
calculated using the interclass correlation coefficient. All data
was analyzed using SPSS (version 24, IBM, Armonk, NY, USA) or R
statistics (version 3.4.4, The R Foundation).
Results
General patient characteristics
Training cohort
Of all 908 patients, 301 patients from University of Bonn were
included in the training cohort (Fig. 1), of whom 169 were male.
Median age at baseline was 56 (28-85) years. Alcohol was theTraining cohort
301 cirrhotic patients with SPSS and CT scan
(University of Bonn)
Total 908 cirrhotic patie
Establishment of TSA
S-TSA (n = 180)
Follow-up
1-year mortality: 17%
HE: 33%
L-TSA (n = 121)
Follow-up
1-year mortality: 32%
HE: 47%
Fig. 1. Flowchart of patient selection.
1142 Journal of Hepatology 20most common etiology of cirrhosis (57% of patients), while 20%
of patients had chronic viral hepatitis B and/or C infection. Other
etiologies were present in 23% of patients. Most of the patients
were decompensated (Child-Pugh B or C in 59%) with 64% of the
patients exhibiting ascites at time of CT scan; 16% had experi-
enced at least 1 episode of hepatic encephalopathy and 26% had
hepatic encephalopathy at baseline. A history of variceal
bleeding was present in 28% of the patients. Median MELD score
was 13 (6-40). Detailed general characteristics are displayed in
Table 1. Of note, high platelet counts >250×109/L were found in
26 patients, of whom 9 had infection, 3 recent bleeding and 2
iron deficiency, as likely causes for high platelet counts. Median
follow-up time was 15 (0–117) months. Median time from
diagnosis of liver cirrhosis to CT scan was 17 months (0–1,322).
Indications for CT scans are displayed in Table S1.
Follow-up data on survival status was available in 254 pa-
tients (Table 1). During follow-up MELD decreased slightly, while
other prognostic scores (MELD-Na, Child-Pugh) did not change
significantly. Compared to baseline, the rate of patients devel-
oping hepatorenal syndrome (23%) and episodes of hepatic en-
cephalopathy (38%) increased significantly. The rate of patients
with ascites and variceal bleeding did not change significantly
(Table 1). In total, 23 patients were treated with TIPS (16 for
refractory ascites, 7 for variceal hemorrhage) during follow-up.
Detailed analysis of number of TIPS and LT in relation to MELD
is shown in Table S2.
SPSS characteristics. In the training cohort of 301 patients, a total
of 392 SPSS were identified. Most patients had a single SPSS
(70%), while almost one-third (30%) were diagnosed with more
than 1 SPSS (Table 1).
The most common SPSS types were para-umbilical shunts
representing 57% of all shunts, followed by splenorenal shunts
(32%), mesocaval shunts in the gastrorenal vein (5%) and in the
adrenal vein (2%). Infero-mesenterico-caval, right renal vein and
mesorenal shunts were each found in only 1% of SPSS.
Validation cohort
A total of 607 patients from 11 participating centers were
included in the validation cohort (Table S3, Fig. 1). Median agents with SPSS and CT
Validation cohort
607 cirrhotic patients with SPSS and CT scan
(multicentric international)
S-TSA (n = 312)
Follow-up
1-year mortality: 23%
HE: 35%
L-TSA (n = 295)
Follow-up
1-year mortality: 37%
HE: 49%
20 vol. 72 j 1140–1150
Table 1. General characteristics of the training cohort (n = 301).
Parameter History Baseline Follow-up
Median (range) or absolute (percentage)
General
Age [years] 58 (28-85)
Gender [male/female] 169/132 (56/44%)
Etiology of cirrhosis [alcohol, viral, other] 173/60/68 (57/20/23%)
Number of shunts [1/2/3] 213/86/2 (71/29/1%)
Total SPSS area [mm2] 59 (6-881)
Clinical events
Ascites 143 (48%) 194 (64%) 116 (53%)
Variceal Bleeding 85 (28%) 48 (16%) 29 (13%)
Spontaneous Bacterial Peritonitis 20 (7%) 32 (11%) 20 (9%)
Hepatorenal Syndrome 30 (10%) 49 (16%) 50 (23%)***
Hepatic Encephalopathy 47 (16%) 78 (26%) 84 (38%)***
Scores
MELD 13 (6-40) 12.5 (6-40)*
MELD-Na 15 (6-40) 14 (6-40)
Child-Pugh 7 (5-13) 7 (5-12)
Child-Pugh class A/B/C 103/143/34 (34/48/11%) 90/68/32 (41/31/15%)
CLIF-C AD 20.65 (10-29) 20.58 (9-32)
Laboratory
Sodium [mmol/L] 138 (119-154) 140 (119-163)***
Creatinine [mg/dl] 0.97 (0.3-6.04) 1 (0.1-9.39)***
Bilirubin [mg/dl] 1.86 (0.21-48.44) 1.75 (0.19-42.49)
AST [U/L] 52 (12-653) 44.5 (9-5,644)
ALT [U/L] 31 (8-349) 33 (6-1,952)
Albumin [g/L] 29.2 (3.2-59.9) 32.8 (3.2-55)***
INR 1.2 (0.9-4.6) 1.2 (0.9-5.3)
WBC [103/ll] 5.86 (1.02-37.17) 5.795 (0.04-36.22)
Platelets [×109/L] 105.5 (11-653) 107.5 (14-479)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation; INR, international normalized ratio;
MELD, model of end-stage liver disease; SPSS, spontaneous portosystemic shunts; WBC, white blood cell count.
*p <0.05; **p <0.01; ***p <0.001.was 58 (18-87) years with 65% male patients. Alcohol was the
most common etiology of cirrhosis (43%), while 27% had viral
hepatitis. Most patients (66%) had decompensated cirrhosis
(Child-Pugh B or C); 53% of the patients had ascites at the time of
CT scan, 30% had experienced at least 1 episode of hepatic en-
cephalopathy, and 25% had hepatic encephalopathy at baseline. A
history of variceal bleeding was present in 25% of the patients.
Median MELD score was 13 (6-37). Detailed general character-
istics are displayed in Table 2.
Follow-up data is shown in Table 2. Briefly, like the training
cohort, the rate of patients developing hepatorenal syndrome
(11%), as well as episodes of hepatic encephalopathy (42%)
increased significantly compared to baseline. The rate of ascites
and variceal bleeding did not change significantly (Table 2).
SPSS characteristics
In the validation cohort of 607 patients, 754 SPSS were identi-
fied. The majority of patients had a single SPSS (79%), while 21%
had multiple SPSS (Table 2). Splenorenal shunts were the most
common, representing 41% of cases, followed by para-umbilical
shunt (35%). Mesocaval shunt was present in 7% of cases, gas-
trorenal in 6%, infero-mesenterico-caval in 3% and mesorenal in
1% of SPSS.
Patient stratification by total SPSS area
A receiver-operating characteristics analysis of TSA with
1-year survival as an endpoint was performed and an area
under the curve of 0.609 (95% CI 0.531–0.687, p = 0.007) was
calculated. The optimal cut-off value for the training cohort
was found at 83 mm2 (sensitivity 55.7%, specificity 66.8%,Journal of Hepatology 20positive predictive value 39.0%, negative predictive value
79.9%; Table S4). Patients with TSA above 83 mm2 (corre-
sponding to a single shunt of 10 mm diameter) were classified
as having large TSA (L-TSA) and patients with TSA below 83
mm2 were classified as having small TSA (S-TSA). Median TSA
was 59 mm2 (6–881). Patients with S-TSA had a median TSA of
35 mm2 (6–82) and L-TSA of 141.46 mm2 (83–881) (Table 3). In
total, 180 patients were classified as S-TSA (60%) and 121 as
L-TSA (40%). There were no significant differences in type of
SPSS between patients with S-TSA and L-TSA. Time between
diagnosis of cirrhosis and CT scan was not significantly
different between patients with S-TSA and L-TSA (15 (0–1,322)
vs. 24 (0–369) months, p = 0.503).
Patients with L-TSA had significantly higher rates of multiple
SPSS, as well as higher MELD scores (14 vs. 11). Moreover, pa-
tients with L-TSA had higher rates of hepatic encephalopathy in
their medical history (Table 3). During follow-up, MELD (12 vs.
15, p <0.01) and MELD-Na (13 vs. 16, p <0.05) score remained
significantly higher in the L-TSA compared to S-TSA group. CLIF-C
AD score was not significantly different. Additionally, Child-Pugh
score (6 vs. 7, p <0.05) in follow-up showed higher values for
L-TSA. This mainly derives from serum albumin levels being
significantly lower in L-TSA (35 vs. 31 g/L, p <0.001) (Table 3). No
significant differences were detectable in terms of hepatorenal
syndrome, ascites and infections.L-TSA is associated with hepatic encephalopathy
Training cohort
Patients with L-TSA had a significantly higher risk of developing
hepatic encephalopathy, as shown by the cumulative hazard20 vol. 72 j 1140–1150 1143
Table 2. General characteristics of external validation cohort (n = 607).
Parameter History Baseline Follow-up
Median (range) or absolute (percentage)
General
Age [years] 58 (18-87)
Sex male/female 397/210 (65/35%)
Etiology of cirrhosis alcohol/viral/others 259/164/184 (43/27/30%)
Number of shunts 1/2/3/4 480/110/14/3 (79/18/2/1%)
Total SPSS area [mm2] 79 (13-2205)
Clinical events
Ascites 345 (58%) 321 (53%) 341 (57%)
Variceal bleeding 151 (25%) 65 (11%) 96 (16%)
Spontaneous bacterial peritonitis 65 (11%) 39 (7%) 72 (12%)
Hepatorenal syndrome 18 (3%) 23 (4%) 63 (11%)***
Hepatic encephalopathy 183 (30%) 152 (25%) 247 (42%)***
Scores
MELD 13 (6-37)
MELD-Na 15 (6-40)
Child-Pugh 8 (5-15)
Child-Pugh class A/B/C 195/238/147 (34/41/25%)
Laboratory
Sodium [mmol/L] 138 (95-164)
Creatinine [mg/dl] 0.8 (0.3-9.2)
Bilirubin [mg/dl] 1.8 (0.1-45.2)
Albumin [g/L] 32 (10-50)
INR 1.4 (0.9-5.2)
Platelets [×109/L] 87 (13-436)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation; INR, international normalized ratio;
MELD, model of end-stage liver disease; SPSS, spontaneous portosystemic shunts; WBC, white blood cell count.
*p <0.05; **p <0.01; ***p <0.001.
Research Article Cirrhosis and Liver Failurefunction for hepatic encephalopathy in Fig. 2A. Blood ammonia
levels were available in 154 patients. Median blood ammonia
level was 65 lmol/L (9–260). Patients were divided into high
(>65 lmol/L) and low (<−65 lmol/L) ammonia levels. Patients
with L-TSA showed higher rates (57%) of high ammonia levels
than patients with S-TSA (42%) (Table S5).Validation cohort
In the validation cohort clinical but no blood parameters were
available at follow-up (Table 4). Importantly, the significantly
higher rates of episodes of hepatic encephalopathy were
confirmed as shown in Fig. 2B.Large TSA is an independent risk factor for 1-year mortality
Training cohort
One-year survival data was available in 253 patients. Fig. 3A
shows the Kaplan-Meier curve for 1-year mortality. The Kaplan-
Meier curve for 1-year survival excluding patients with high
platelet counts showed similar results (Fig. S2). Patients with
L-TSA had a significantly higher mortality compared to patients
with S-TSA (p <0.001). Most deaths are attributed to infection
(63%). Hepatocellular carcinoma and liver failure caused 10% and
13% of deaths, respectively. Six percent died of bleeding and
cardiovascular events (Table S6).
Univariate Cox regression was performed to identify risk
factors for 1-year mortality. This revealed that besides the ex-
pected prognostic MELD score, creatinine, bilirubin and INR, as
well as hepatorenal syndrome, hepatic encephalopathy, sponta-
neous bacterial peritonitis, ascites and L-TSA at baseline were
dependent predictors of survival. Multivariate Cox regression
identified L-TSA alongside MELD, hepatic encephalopathy, hep-
atorenal syndrome and ascites as independent risk factors for
1-year survival (Table 5).1144 Journal of Hepatology 20A different model with TSA as a continuous variable was
calculated, which confirmed TSA (as a continuous variable) as an
independent predictor of 1-year survival (Table S7).
Validation cohort
In order to validate these results, the validation cohort was
stratified for TSA. A total of 312 patients were classified as S-TSA
(51%) and 295 as L-TSA (49%). Patients with L-TSA had signifi-
cantly higher MELD and Child-Pugh score. There were no sig-
nificant differences in type of SPSS between patients with S-TSA
and L-TSA. Moreover, patients with L-TSA had higher rates of
hepatic encephalopathy at baseline and in their medical history
(Table 4). Survival data was available in 604 patients. Fig. 3B
shows the Kaplan-Meier curve for 1-year mortality. Patients with
L-TSA had a significantly higher mortality compared to those
with S-TSA (p <0.001). Kaplan-Meier curve for 1-year survival
excluding patients with high platelet counts showed similar re-
sults (Fig. S3).
Most deaths in the validation cohort were attributed to liver
failure (36%), infection (19%) and hepatocellular carcinoma (12%).
Six percent died of bleeding, 27% died of other or unknown
causes (Table S8).
Univariate Cox regression was performed to identify risk
factors for 1-year mortality. In this validation cohort prognostic
markers such as MELD, creatinine, bilirubin and INR, as well as
hepatorenal syndrome, hepatic encephalopathy, spontaneous
bacterial peritonitis, ascites and TSA at baseline were dependent
predictors of survival. Multivariate Cox regression confirmed TSA
and MELD as independent predictors of 1-year mortality.
Moreover, age, hepatorenal syndrome and ascites were shown as
independent risk factors for 1-year survival (Table 6).
In an alternative model using TSA as a continuous variable,
TSA was still an independent predictor of 1-year mortality,
suggesting a linear relationship (Table S9).20 vol. 72 j 1140–1150
Table 3. Clinical and laboratory characteristics of training cohort stratified for total shunt area.
Parameter S-TSA L-TSA
Median (range) or absolute (percentage) n = 180 n = 121
Baseline general
Age [years] 57 (28-85) 58 (31-78)
Sex male/female 99/81 (55/45%) 70/51 (58/42%)
Etiology of cirrhosis alcohol/viral/others 103/41/36 (57/23/20%) 70/19/32 (58/16/26%)
Number of shunts 1/2/3 162/18/0 (90/10/0%) 51/68/2 (42/56/2%)***
Total SPSS area [mm2] 34.72 (5.72-82.34) 141.46 (83.29-880.65)***
History of clinical events
Ascites 89 (49%) 54 (45%)
Variceal bleeding 48 (27%) 37 (31%)
Spontaneous bacterial peritonitis 12 (7%) 8 (7%)
Hepatorenal syndrome 19 (11%) 11 (9%)
Hepatic encephalopathy 22 (12%) 25 (21%)*
Baseline clinical events
Ascites 126 (70%) 68 (56%)*
Variceal bleeding 34 (19%) 14 (12%)
Spontaneous bacterial peritonitis 18 (10%) 14 (12%)
Hepatorenal syndrome 26 (14%) 23 (19%)
Hepatic encephalopathy 42 (23%) 36 (30%)
Baseline scores
MELD 11 (6-35) 14 (6-40)***
MELD-Na 14 (6-36) 16 (6-40)**
Child-Pugh 7 (5-11) 7 (5-13)
Child-Pugh class A/B/C 63/91/13 (35/51/7%) 40/52/21 (33/43/17%)
Baseline laboratory
Sodium [mmol/L] 138 (119-148) 139 (122-154)
Creatinine [mg/dl] 0.96 (0.3-6.04) 0.99 (0.42-5.09)
Bilirubin [mg/dl] 1.56 (0.21-19.9) 2.45 (0.26-48.44)***
Albumin [g/L] 29.4 (3.2-51.6) 28.9 (4.8-59.9)
INR 1.2 (0.9-2.8) 1.3 (1-4.6)***
Parameter S-TSA L-TSA
Median (range) or absolute (percentage) n = 180 n = 121
FU
Survival FU 1 year [months] 12 (0-12) 8.5 (0-12)*
FU state 1-year dead/LT 22 / 9 (17%) 29 /10 (32%)**
Lost to FU 36 (20%) 23 (19%)
FU clinical events
Ascites 76 (55%) 40 (49%)
Variceal bleeding 22 (16%) 7 (9%)
Spontaneous bacterial peritonitis 14 (10%) 6 (7%)
Hepatorenal syndrome 33 (24%) 17 (21%)
Hepatic encephalopathy 46 (33%) 38 (47%)*
FU scores
MELD 12 (6-40) 15 (6-40) **
MELD-Na 13 (6-40) 16 (6-40)*
Child-Pugh 6 (5-12) 7 (5-12)*
Child-Pugh class A/B/C 63/41/14 (46/30/10%) 27/27/18 (33/33/22%)*
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation; FU, follow-up; INR, international
normalized ratio; LT, liver transplantation; L-TSA, large total SPSS area; MELD, model of end-stage liver disease; SPSS, spontaneous portosystemic shunts; S-TSA, small total
SPSS area; WBC, white blood cell count.
*p <0.05; **p <0.01; ***p <0.001.To further investigate the impact of TSA on survival in relation
to liver function, we divided the whole cohort into tertiles ac-
cording to MELD (6–9, 10–13, 14–40), as in our previous study.15
The rates of 1-year mortality were higher in the L-TSA group and
significant in MELD groups 6–9 and 14–40 (Table S10).
SPSS and TSA distribution
In our recent multicenter study,15 a stratification of patients ac-
cording to SPSS diameter (8 mm cut-off) did not show significant
differences in survival between S-SPSS (<8 mm) and L-SPSS (>−8
mm). Therefore, we investigated the distribution of S-/L-SPSS
and S-/L-TSA of the whole cohort. The results are shown in
Fig. S4. In total, 35% of patients were classified S-SPSS and S-TSA,Journal of Hepatology 200.3% S-SPSS and L-TSA, 19% L-SPSS and S-TSA and 46% L-SPSS and
L-TSA. This suggests mostly concordant classification between
S-SPSS and S-TSA. However, a substantial fraction (19%) of
patients with L-SPSS are classified as S-TSA as well.
The Kaplan-Meier survival curve shows no significant differ-
ence in survival between patients with S-SPSS and L-SPSS
(Fig. S5), confirming our previous study.15 Importantly, Kaplan-
Meier survival analysis of only patients with L-SPSS showed a
highly significant difference between patients classified as S-TSA
and L-TSA, demonstrating that TSA classification clearly out-
performs classification by SPSS diameter (Fig. S6).
We performed a Cox regression model for 1-year survival
with L-SPSS instead of L-TSA to evaluate the predictive value of20 vol. 72 j 1140–1150 1145
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Research Article Cirrhosis and Liver Failurepresence of L-SPSS. In both the training and validation cohort
SPSS was not significant in multivariate analysis. In the valida-
tion cohort, SPSS was not significant in the univariate analysis
either (Table S11 and S12).
Discussion
Using a large single center training and a large multicentric in-
ternational validation cohort, this study demonstrates for the
first time that portosystemic shunting is associated with
increased mortality in cirrhotic patients independently of
severity of liver disease.
These results build up on the previously reported data on the
influence of the diameter of largest SPSS, where a clear associ-
ation with the risk of complications of liver cirrhosis was
demonstrated.15 This study confirms those results, which un-
derlines the robustness of TSA. Another factor supporting the
plausibility of our data is the fact that L-TSA was found in more
advanced stages of liver cirrhosis, reflected by higher MELD
scores, which is in line with previous reports.15,25 One might
argue that retrieving and calculating the cross-sectional area of
every SPSS is costly and more time consuming than just
measuring the diameter of the largest SPSS. However, having a
single SPSS of 10 mm diameter or more qualifies for L-TSA but
not multiple SPSS with an added diameter of 10 mm. This situ-
ation of multiple SPSS is present in one-third of the presented
large cohort. The present study demonstrates that the complete
shunting volume, which might be better reflected by TSA, gives
independent insight into the progression of liver disease and
outcome of cirrhotic patients. This hypothesis is supported by
this study because the size of TSA has an independent impact on
survival in cirrhotic patients, which could not be demonstrated
for diameter of the single largest SPSS (<8 mm vs. >−8 mm).
15
This is especially impactful because, as shown in our and1146 Journal of Hepatology 20other cohorts, about one-third of the patients have more than
1 SPSS.15,26,27 Since this study demonstrates TSA as a risk factor
for survival independent of MELD, an incorporation of TSA in
MELD (TSA-MELD) could improve patient’s risk stratification
and should be evaluated in future research.
The association of hepatic encephalopathy and SPSS is well
established.7,15,28–31 This association with hepatic encephalopa-
thy is not only apparent for spontaneous shunts but also for
therapeutically implanted shunts (e.g. TIPS and surgical shunts),
where episodes of hepatic encephalopathy occur in up to 50% of
patients.31–33 Although only shown in a few cohorts, the dele-
terious effect of shunting seems to be additive by the number
shunts (spontaneous and intentional) as the presence of SPSS
and TIPS has been shown to be associated with more compli-
cations than TIPS alone.34,35 Growing evidence has been pub-
lished that suggests less complications after TIPS by using
smaller diameter stents or dilatation of stents smaller than the
nominal diameter, suggesting a beneficial effect of less shunt
volume.36–40
Regarding other decompensating events, we were unable to
find a significant difference in variceal bleeding, hepatorenal
syndrome or spontaneous bacterial peritonitis between patients
with L-TSA and S-TSA. Considering variceal bleeding, our data are
supported by previous reports, in which only the presence of
SPSS vs. no SPSS was shown to be associated with bleeding, but
no differences between small and large SPSS were
detected.7,10,15,29
Interestingly, the cut-off we found in our patients corre-
sponds to a single shunt of 10 mm diameter. In non-spontaneous
SPSS, such as TIPS, it has been previously shown that small
diameter TIPS-shunts are associated with less hepatic encepha-
lopathy and better survival than the commonly used 10 mm
stents.37,38,40 However, in case of TIPS, the collaterals and the20 vol. 72 j 1140–1150
Table 4. Clinical and laboratory characteristics of validation cohort stratified for total shunt area.
Parameter S-TSA L-TSA
Median (range) or absolute (percentage) n = 312 n = 295
Baseline general
Age [years] 59 (18-87) 57 (20-84)
Sex male/female 209/103 (67/33%) 188/107 (64/36%)
Etiology of cirrhosis alcohol/viral/others 129/86/97 (41/28/31%) 130/78/87 (44/26/30%)
Number of shunts 1/2/3 283/27/2/0 (91/8/1/0%) 67/28/12/3 (67/28/4/1%)***
Total SPSS area [mm2] 38 (13-79) 201 (89-2205)***
History of clinical events
Ascites 180 (58%) 165 (57%)
Variceal bleeding 75 (25%) 76 (26%)
Spontaneous bacterial peritonitis 37 (12%) 28 (10%)
Hepatorenal syndrome 9 (3%) 9 (3%)
Hepatic encephalopathy 71 (23%) 112 (38%)***
Baseline clinical events
Ascites 176 (56%) 145 (49%)
Variceal bleeding 42 (14%) 23 (8%)*
Spontaneous bacterial peritonitis 22 (7%) 17 (6%)
Hepatorenal syndrome 15 (5%) 8 (3%)
Hepatic encephalopathy 64 (21%) 88 (30%)**
Baseline scores
MELD 12 (6-37) 14 (6-33)**
MELD-Na 15 (6-37) 15 (6-40)
Child-Pugh 8 (5-15) 8 (5-15)*
Child-Pugh class A / B / C 109/120/73 (36/40/24%) 86/118/74 (31/42/27%)
Baseline laboratory
Sodium [mmol/L] 137 (117-164) 138 (95-148)
Creatinine [mg/dl] 0.8 (0.3-3.8) 0.8 (0.4-9.2)
Bilirubin [mg/dl] 1.5 (0.1-42.9) 2.1 (0.3-45.2)*
Albumin [g/L] 32 (10-50) 32 (15-50)
INR 1.4 (0.9-5.2) 1.4 (1.0-4.1)
Parameter S-TSA L-TSA
Median (range) or absolute (percentage) n = 312 n = 295
FU
Survival FU 1 year [months] 12 (0-12) 11 (0-12)*
FU state 1-year dead/LT 45/28 (23%) 78/31 (37%)***
Lost to FU 42 (13%) 56 (19%)
FU clinical events
Ascites 182 (59%) 159 (56%)
Variceal bleeding 55 (18%) 41 (14%)
Spontaneous bacterial peritonitis 37 (12%) 35 (12%)
Hepatorenal syndrome 34 (11%) 29 (10%)
Hepatic encephalopathy 107 (35%) 140 (49%)***
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIF-C AD, Chronic Liver Failure Consortium acute decompensation; FU, follow-up; INR, international
normalized ratio; LT, liver transplantation; L-TSA, large total SPSS area; MELD, model of end-stage liver disease; SPSS, spontaneous portosystemic shunts; S-TSA, small total
SPSS area; WBC, white blood cell count.
*p <0.05; **p <0.01; ***p <0.001.other SPSS have been rigorously embolized in order to limit TSA
to 10 mm and other persisting collaterals (in many patients
present) may have contributed to non-significant results
regarding survival.
This study presents a large, multicentric, international, well
characterized cohort of cirrhotic patients with SPSS. However, it
has several limitations, which are mainly based on the retro-
spective nature of the study. Some parameters such as endos-
copy and follow-up blood work were not available in all patients.
Patients were not specifically screened for non-cirrhotic portal
hypertension. Moreover, exploring a pathophysiological mecha-
nism is beyond the scope of this study. Longitudinal data of the
impact of SPSS on the natural history are needed. The develop-
ment of portal venous thrombosis and its relation to medical
treatment, such as non-selective betablockers and anticoagu-
lants, should be addressed in future longitudinal studies.41–45 In
this study only cirrhotic patients who underwent CT scan wereJournal of Hepatology 20included. This would lead to a selection bias towards patients
without severe kidney dysfunction because those patients would
not receive CT scan due to contrast media exposure. Moreover,
no data on sarcopenia is available, which has recently been
recognized as a risk factor for the development of hepatic en-
cephalopathy after TIPS46–50 and could be a competing factor to
consider against TSA.
In conclusion, this study highlights, for the first time, the
prognostic importance of TSA (sum of all cross-sectional SPSS
areas) in patients with mostly decompensated liver cirrhosis. The
prevalence of more than 1 SPSS among these patients is high and
increases with advancing liver disease. L-TSA is an independent
predictor of 1-yearmortality and is associatedwith higher rates of
hepatic encephalopathy compared to S-TSA. These data suggest
that there is a cut-off for portosystemically shunted blood volume
where the beneficial effects are outweighed by the deleterious
ones. Our results support the clinical use of TSA/SPSS for risk20 vol. 72 j 1140–1150 1147
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Fig. 3. Kaplan-Meier curve of 1-year survival in training and validation cohorts. (A) Kaplan-Meier curve showing impaired 1-year survival in L-TSA patients
(green line) compared to S-TSA patients (blue line) in training cohort. (B) Kaplan-Meier curve showing impaired 1-year survival in L-TSA patients (green line)
compared to S-TSA patients (blue line) in validation cohort. (S-/L-TSA: small (<83 mm2) / large (>−83 mm
2) total SPSS area). Statistical analysis: log-rank test. L-TSA,
large total SPSS area; SPSS, spontaneous portosystemic shunts; S-TSA, small total SPSS area.
Table 5. Univariate and multivariate Cox regression analysis of training cohort with 1-year mortality as endpoint.
Univariate Cox regression Multivariate Cox regression
Parameter HR 95% CI p value HR 95% CI p value
Age1 1.027 1.003 1.051 0.025 1.060 <0.001 1.089 <0.001
Sex 0.332
L-TSA 2.266 1.407 3.650 0.001 1.660 0.040 2.695 0.040
Hepatic encephalopathy at baseline 3.519 2.190 5.657 <0.001 2.204 0.002 3.619 0.002
Hepatorenal syndrome at baseline 5.781 3.561 9.386 <0.001 1.890 0.024 3.283 0.024
Ascites at baseline 2.566 1.427 4.615 0.002 0.507 0.507
SBP at baseline 2.736 1.541 4.857 0.001 0.693 0.693
MELD at baseline 1.180 1.144 1.217 <0.001 1.175 <0.001 1.222 <0.001
Sodium at baseline2 0.950 0.909 0.993 0.022
Creatinine at baseline3 2.171 1.783 2.643 <0.001
Bilirubin at baseline3 1.122 1.092 1.153 <0.001
INR at baseline 4.469 3.221 6.202 <0.001
1years; 2mmol/L; 3mg/dl
Italic, included in multivariate analysis; Bold, significant in multivariate analysis.
INR, international normalized ratio; L-TSA, large total SPSS area; MELD, model of end-stage liver disease; SBP, spontaneous bacterial peritonitis; SPSS, spontaneous porto-
systemic shunts.
Research Article Cirrhosis and Liver Failurestratification and decision-making in themanagement of patients
with cirrhosis.Abbreviations
ALT, alanine aminotransferase; AST, aspartate aminotransferase;
CLIF-C AD, Chronic Liver Failure Consortium acute decompen-
sation; FU, follow-up; HR, hazard ratio; HRS, hepatorenal syn-
drome; INR, international normalized ratio; LT, liver
transplantation; L-TSA, large total SPSS area; MELD, model of
end-stage liver disease; SBP, spontaneous bacterial peritonitis;
SPSS, spontaneous portosystemic shunts; S-TSA, small total SPSS
area; TIPS, transjugular intrahepatic portosystemic shunt; WBC,
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